RMDA Statistics

Total Valuation

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. has a market cap or net worth of EGP 5.50 billion. The enterprise value is 6.27 billion.

Market Cap	5.50B
Enterprise Value	6.27B

Important Dates

The next estimated earnings date is Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	Jun 25, 2024

Share Statistics

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. has 1.50 billion shares outstanding. The number of shares has increased by 1.53% in one year.

Shares Outstanding	1.50B
Shares Change (YoY)	+1.53%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	2.64%
Owned by Institutions (%)	11.37%
Float	862.70M

Valuation Ratios

The trailing PE ratio is 24.15 and the forward PE ratio is 12.08.

PE Ratio	24.15
Forward PE	12.08
PS Ratio	2.60
PB Ratio	3.12
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.30, with an EV/FCF ratio of -56.67.

EV / Earnings	27.65
EV / Sales	2.98
EV / EBITDA	11.30
EV / EBIT	13.13
EV / FCF	-56.67

Financial Position

The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.59.

Current Ratio	1.51
Quick Ratio	0.62
Debt / Equity	0.59
Debt / EBITDA	1.88
Debt / FCF	-9.43
Interest Coverage	1.89

Financial Efficiency

Return on equity (ROE) is 15.11% and return on invested capital (ROIC) is 10.62%.

Return on Equity (ROE)	15.11%
Return on Assets (ROA)	9.33%
Return on Capital (ROIC)	10.62%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.66
Inventory Turnover	2.86

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +154.17% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+154.17%
50-Day Moving Average	2.63
200-Day Moving Average	2.38
Relative Strength Index (RSI)	76.43
Average Volume (20 Days)	22,865,421

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. had revenue of EGP 2.10 billion and earned 226.67 million in profits. Earnings per share was 0.15.

Revenue	2.10B
Gross Profit	985.45M
Operating Income	477.41M
Pretax Income	333.45M
Net Income	226.67M
EBITDA	550.66M
EBIT	477.41M
Earnings Per Share (EPS)	0.15

Full Income Statement

Balance Sheet

The company has 297.45 million in cash and 1.04 billion in debt, giving a net cash position of -745.85 million or -0.50 per share.

Cash & Cash Equivalents	297.45M
Total Debt	1.04B
Net Cash	-745.85M
Net Cash Per Share	-0.50
Equity (Book Value)	1.78B
Book Value Per Share	1.17
Working Capital	700.67M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -46.00 million and capital expenditures -64.58 million, giving a free cash flow of -110.58 million.

Operating Cash Flow	-46.00M
Capital Expenditures	-64.58M
Free Cash Flow	-110.58M
FCF Per Share	-0.07

Full Cash Flow Statement

Margins

Gross margin is 46.90%, with operating and profit margins of 22.72% and 11.80%.

Gross Margin	46.90%
Operating Margin	22.72%
Pretax Margin	15.87%
Profit Margin	11.80%
EBITDA Margin	26.21%
EBIT Margin	22.72%
FCF Margin	-5.26%

Dividends & Yields

This stock pays an annual dividend of 0.07, which amounts to a dividend yield of 1.83%.

Dividend Per Share	0.07
Dividend Yield	1.83%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	20.67%
Buyback Yield	-1.53%
Shareholder Yield	0.31%
Earnings Yield	4.14%
FCF Yield	-2.01%

Dividend Details

Stock Splits

The last stock split was on September 21, 2023. It was a forward split with a ratio of 1.52253.

Last Split Date	Sep 21, 2023
Split Type	Forward
Split Ratio	1.52253

Scores

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. has an Altman Z-Score of 3.01.

Altman Z-Score	3.01
Piotroski F-Score	n/a